Long-term outcomes of long-acting injection antipsychotic treatment in patients with schizophrenia

Objective of the study: to evaluate efficiency of antipsychotic therapy with long-acting agents for patients with paranoid schizophrenia. Material: 75 cases of patients with paranoid schizophrenia under therapy with LAI were analyzed: paliperidone palmitate (n=40) or haloperidol decanoate (n=35) for 24 months after achieving remission in 2013-2017. The analysis included also data of 35 patients who continued the LAI therapy at St. Petersburg Psychoneurological Dispensary no. 5 12 months more. Tasks of observation: to study dynamics of mental health of patients against the background of intake of LAI, to compare efficiency and safety of LAI of the first and second generations, to evaluate quality of remission. Methods: clinical-dynamic (PANSS, PSP, CGI), statistical (method of descriptive statistics). Results: In order to improve therapeutic strategies long-acting injection antipsychotics (LAI) should be used as an effective method of monitoring adherence and disease. There are approaches to the use of LAI in modern psychiatry and the data of the observation of the first and second generation LAI administration for 24 months in routine clinical practice. Well-timed intervention and continuity of treatment are decisive for achieving long-term remission, preventing a malicious course of the disease and reducing the costs and the burden of the disease.